Formula Pharma by Mark JC Nuijten.

work info

a2m, partner of Minerva Network, develops multicountry health economic models for its clients all over the world: cost-effectiveness models and budget impact models.

The models by a2m successfully contributed to positive reimbursement decisions by health authorities in many countries. read more

a2m has established strategic global collaborations with key local market access and reimbursement experts in the key European markets, as well as the US, Canada and Japan for preparation of reimbursement dossiers (e.g. TLV in Sweden, SMC in Scotland, RIZIV in Belgium, and CVZ in The Netherlands).


Economic impact of macrosomia

Dr Nuijten, CEO of a2m, is a pioneer in the field of nutrition-economics and has been the first classical health economist applying and developing health economic methodologies to nutritionals. He is founder of the ISPOR Special Interest Group “Nutrition Economics” and recently published his 15th scientific paper in nutrition economics, titled “Health economic modelling to assess short-term costs of maternal overweight, gestational diabetes and related macrosomia” in Frontiers in Pharmacology. This pilot study shows the initial results of ongoing health economic modelling research projects in this area.